Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Apitolisib |
| Trade Name | |
| Synonyms | GDC-0980 |
| Drug Descriptions |
Apitolisib (GDC-0980) is an inhibitor of both PI3K and mTOR kinases, resulting in decreased phosphorylation of PI3K/Akt/mTOR pathway markers, which may lead to inhibition of tumor growth and tumor regression (PMID: 21998291, PMID: 30914027). |
| DrugClasses | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 |
| CAS Registry Number | 1032754-93-0 |
| NCIT ID | C91731 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Ado-trastuzumab emtansine + Apitolisib | Ado-trastuzumab emtansine Apitolisib | 0 | 0 |
| Apitolisib | Apitolisib | 11 | 3 |
| Apitolisib + Mirdametinib | Apitolisib Mirdametinib | 0 | 0 |
| Apitolisib + Palbociclib | Apitolisib Palbociclib | 0 | 0 |
| Apitolisib + Trastuzumab | Apitolisib Trastuzumab | 0 | 0 |